The DoD is offering the PRMRP Focused Program Award to accelerate solutions through synergistic, multidisciplinary research programs.

The FY22 PRMRP Focused Program Award (FPA) is intended to optimize research and accelerate solutions to a critical question related to one of the congressionally directed FY22 PRMRP Topic Areas and one of the FY22 PRMRP Strategic Goals through a synergistic, multidisciplinary research program.

Key aspects of this award include:

Overarching Challenge: FPA applications must describe a unifying, overarching challenge that will be addressed by a set of research projects. The overarching challenge must be relevant to a critical problem or question in the field of research and/or patient care in one of the FY22 PRMRP Topic Areas and one of the FY22 PRMRP Strategic Goals.

Research Projects: Applications shall include multiple, distinct research projects led by individual project leaders that address complementary aspects of the overarching challenge. Applicants are strongly encouraged to submit a minimum of four research projects; additional studies are allowed. While individual projects must be capable of standing on their own high scientific merits, they must also be interrelated and synergistic with the other proposed projects and advance a solution beyond what would be possible through individual efforts. The exploration of multiple hypotheses or viewpoints of the same line of questioning is encouraged. This award mechanism is not intended to support a series of research projects that are dependent on the success of one of the other projects. Each project should propose a unique approach to addressing the overarching challenge and be capable of producing research findings with potential to impact the field and/or patient care. Individual research projects may range from exploratory, hypothesis-developing studies through small-scale clinical trials (i.e., up to and including phase 2 or equivalent). There should be a clear intent to progress toward translational/ clinical work over the course of the effort. If an Investigational New Drug (IND) or Investigational Device Exemption (IDE) will be required to support a project that includes some preclinical work to be completed prior to an early-phase (pilot, phase 1, phase 2, or equivalent) clinical trial, then a proposed submission date of the IND or IDE application to the U.S. Food and Drug Administration (FDA) should be included in the application.